Ticker

Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership. Profitability This table compares Brainstorm Cell

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $0.66 and traded as high as $0.9479. Brainstorm Cell Therapeutics shares last traded at $0.85, with a volume of 8,002 shares

Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence Company highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteria NEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative…

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.65 and traded as high as $0.90. Brainstorm Cell Therapeutics shares last traded at $0.87, with a volume of 9,450 shares. Brainstorm Cell Therapeutics Stock

Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) is anticipated to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Brainstorm Cell Therapeutics to post earnings of ($0.28) per share for the quarter. Interested persons can find conference call details on the company's upcoming Q4 2025 earning report page